Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone. 2018 Oct 22;120:137-140. doi: 10.1016/j.bone.2018.10.015

Miller PD(1), Hattersley G(2), Lau E(3), Fitzpatrick LA(4), Harris AG(5), Williams GC(4), Hu MY(4), Riis BJ(6), Russo L(7), Christiansen C(6).

DOI: 10.1016/j.bone.2018.10.015  -PMID: 30359763

https://www.ncbi.nlm.nih.gov/pubmed/30359763
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada